CDK4/6 inhibitors in breast cancer: spotting the difference

  • Nat Med. 2021 Nov;27(11):1868-1869. doi: 10.1038/s41591-021-01570-9.
Jose Manuel Perez-Garcia  1  2  3 ,  Javier Cortes  4  5  6  7  8 ,  Antonio Llombart-Cussac  2  3  9
Affiliations
  • 1. Oncology Department, International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain.
  • 2. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
  • 3. Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA.
  • 4. Oncology Department, International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. [email protected].
  • 5. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. [email protected].
  • 6. Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. [email protected].
  • 7. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. [email protected].
  • 8. Breast Cancer Research program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [email protected].
  • 9. Oncology Department, Arnau de Vilanova University Hospital, Valencia, Spain.
PMID: 34750558 DOI: 10.1038/s41591-021-01570-9
Products